- Home
- TSLX vs VRNA Comparison
TSLX vs VRNA Comparison
Compare TSLX & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSLX
- VRNA
- Stock Information
- Founded
- TSLX 2010
- VRNA 2005
- Country
- TSLX United States
- VRNA United Kingdom
- Employees
- TSLX N/A
- VRNA N/A
- Industry
- TSLX Investment Managers
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- TSLX Finance
- VRNA Health Care
- Exchange
- TSLX Nasdaq
- VRNA Nasdaq
- Market Cap
- TSLX 1.9B
- VRNA 2.2B
- IPO Year
- TSLX 2014
- VRNA 2017
- Fundamental
- Price
- TSLX $20.36
- VRNA $35.66
- Analyst Decision
- TSLX Strong Buy
- VRNA Strong Buy
- Analyst Count
- TSLX 7
- VRNA 6
- Target Price
- TSLX $22.07
- VRNA $43.83
- AVG Volume (30 Days)
- TSLX 384.0K
- VRNA 1.1M
- Earning Date
- TSLX 11-05-2024
- VRNA 11-04-2024
- Dividend Yield
- TSLX 11.64%
- VRNA N/A
- EPS Growth
- TSLX N/A
- VRNA N/A
- EPS
- TSLX 2.06
- VRNA N/A
- Revenue
- TSLX $478,363,000.00
- VRNA $5,624,000.00
- Revenue This Year
- TSLX $10.92
- VRNA N/A
- Revenue Next Year
- TSLX N/A
- VRNA $554.09
- P/E Ratio
- TSLX $9.88
- VRNA N/A
- Revenue Growth
- TSLX 14.25
- VRNA 1127.95
- 52 Week Low
- TSLX $19.50
- VRNA $11.39
- 52 Week High
- TSLX $22.35
- VRNA $40.13
- Technical
- Relative Strength Index (RSI)
- TSLX 45.67
- VRNA 51.76
- Support Level
- TSLX $19.69
- VRNA $36.49
- Resistance Level
- TSLX $20.55
- VRNA $40.13
- Average True Range (ATR)
- TSLX 0.32
- VRNA 2.01
- MACD
- TSLX 0.01
- VRNA -0.30
- Stochastic Oscillator
- TSLX 66.28
- VRNA 47.60
About TSLX Sixth Street Specialty Lending Inc.
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.